Diligence memo · auto-generated · as of July 2, 2026
Aerie Pharmaceuticals Inc
Aerie Pharmaceuticals Inc looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Aerie Pharmaceuticals Inc operates in Biotechnology, based in Bedminster.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Aerie Pharmaceuticals Inc has raised $190M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $125M on 2014-09-08.
Most recent recorded round closed around 2014-09-08.
Valuation (modeled)modeled
Provath models Aerie Pharmaceuticals Inc at approximately $5.2B (range $567M–$11.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.18× the median modeled value of Series D+ Biotechnology companies in 2013–2015 (7 peers) — value vs value, same stage and era. Within the normal band (118% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 12 months.
Last raise 11.8 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 41.7× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 96% of Biotechnology peers (4293 compared).
Modeled value ranks above 99% of those peers.
Closest niche peers: Adaptive Biotechnologies Corp, Editas Medicine, Inc., Ngm Biopharmaceuticals Inc, Adaptimmune Ltd, Sequenom Inc.
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.